These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23406552)

  • 1. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
    González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
    Burger RA
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
    Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Marth C; Reimer D; Zeimet AG
    Ann Oncol; 2017 Nov; 28(suppl_8):viii36-viii39. PubMed ID: 29232473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
    Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
    Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapies in epithelial ovarian cancer.
    Teoh DG; Secord AA
    Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line and maintenance therapy for ovarian cancer: current status and future directions.
    González-Martín A; Sánchez-Lorenzo L; Bratos R; Márquez R; Chiva L
    Drugs; 2014 Jun; 74(8):879-89. PubMed ID: 24848752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
    Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
    Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H; Kigawa J
    Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.